Gilead Sciences, Inc. (GILD) Stock Forecast & Price Target
Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 11, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Gilead Sciences, Inc. (GILD), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Gilead Sciences, Inc., analysts forecast revenue rising from $29.23B in 2025 to $39.45B in 2030; the average estimate for 2030 earnings per share is $13.32; with published estimates ranging from $12.69 to $13.81; 21 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Gilead Sciences, Inc. (GILD) forecast — frequently asked questions
What is the analyst price target for Gilead Sciences, Inc.?
Analysts covering Gilead Sciences, Inc. (GILD) have a consensus price target of $165.38, 1.3% below the current price of $167.54. Published targets range from $126.00 to $196.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Gilead Sciences, Inc.'s earnings?
The average analyst estimate for Gilead Sciences, Inc. (GILD) earnings per share in 2030 is 13.32, with individual estimates between 12.69 and 13.81.
How much revenue is Gilead Sciences, Inc. expected to make?
Analysts forecast Gilead Sciences, Inc. (GILD) revenue of $39.45B in 2030, based on 10 published estimates.
How many analysts cover GILD?
21 analysts contribute estimates for Gilead Sciences, Inc. (GILD). Thin coverage makes an average less reliable.
Analyst forecasts for other Drug Manufacturers - General stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.